EUVIMEDEUVIMED entdecken
Crossref

Aprepitant’s roles in abating seizures, behavioral, and cognitive deficits in mice model of epilepsy

Heba A Hassan, Yousef Al-Saraireh

Epilepsy & Behavior · 2024

DOI: 10.1016/j.yebeh.2024.110028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Heba A Hassan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Department, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan. Electronic address: HAHanafi@medicine.zu.edu.eg. Hauptthemen laut MEDLINE: Aprepitant, Disease Models, Animal, Valproic Acid, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aprepitant (APR), a neurokinin 1 receptor antagonist, is an approved drug for treating chemotherapy-induced nausea and vomiting. OBJECTIVES: Investigate the beneficial roles of APR alone or in combination with sodium valproate (VPA) against lithium pilocarpine [li-pilo]-induced seizures, behavioral changes, and cognitive deficits. METHODS: Thirty male mice were divided into five groups, each containing 6. "Vehicle Group I," "Control Group II "li-pilo, " Valproate (VPA) group III (400 mg/kg/i.p.), "APR group IV, " and "Combination Group V." Videos of mice were recorded, and they were watched for episodes of spontaneous recurring seizures (SRS). Behavioral Tests were performed. At the end of the study, animal brains were taken for biochemical assays and gene expression studies. RESULTS: APR partially protected against SRS with partial restoration of average behavioral and standard cognitive skills associated with a significant increase in brain SOD activity and a significant decrease in MDA, IL-1β, NF-КB, and SP-3 levels in relation to the control group. Interestingly, a combination of APR with VPA in epileptic mice showed complete protection against li-pilo-induced behavioral changes and cognitive deficits, a significant increase in brain SOD activity, and a considerable decrease in MDA, IL-1β, NF-ΚB, and SP levels to normal. CONCLUSION: Using APR as an adjuvant to VPA is more effective in protecting against li-pilo-induced seizures, behavioral changes, and cognitive deficits due to its antioxidant, anti-inflammatory, and NK1 antagonist effects than using APR alone as drug therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AprepitantDisease Models, AnimalValproic AcidAnticonvulsantsSeizuresEpilepsyPilocarpineAnimalsMaleMiceMorpholinesBrainCognitive DysfunctionMaze LearningSuperoxide Dismutase

Stichwörter der Autor:innen

AprepitantCognitive and behavioral disabilitiesLi-pilocarpine model of epilepsyNK1 receptor

Substanzen

AprepitantValproic AcidAnticonvulsantsPilocarpineMorpholinesSuperoxide Dismutase

Autor:innen und Institutionen

  • Pharmacology Department, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan. Electronic address: HAHanafi@medicine.zu.edu.eg.
  • Pharmacology Department, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan.

Zitieren

APA

A Hassan, H., & Al-Saraireh, Y. (2024). Aprepitant’s roles in abating seizures, behavioral, and cognitive deficits in mice model of epilepsy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.110028

Vancouver

A Hassan H, Al-Saraireh Y. Aprepitant’s roles in abating seizures, behavioral, and cognitive deficits in mice model of epilepsy. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.110028

BibTeX
@article{AHassan2024,
  author = {A Hassan, Heba and Al-Saraireh, Yousef},
  title = {Aprepitant’s roles in abating seizures, behavioral, and cognitive deficits in mice model of epilepsy},
  journal = {Epilepsy & Behavior},
  year = {2024},
  doi = {10.1016/j.yebeh.2024.110028}
}
Kostenlos starten →